Establishment of precision medicine in pharmacotherapy for castration-resistant prostate cancer

Research output: Contribution to journalArticle

Abstract

Recently, several novel agents including abiraterone, enzalutamide, docetaxel, cabazitaxel and radium-223 have become available for the treatment of castration-resistant prostate cancer (CRPC) and as a result, prognosis has improved. However, the criteria for selection of a suitable therapy have not been established. Much research on the genome has been carried out to enable precision medicine to be applied in cases of CRPC. Among them, germline polymorphisms in genes involved in androgen metabolism, such as HSD3B1, have been supposed to be the critical determinants of therapeutic outcomes in hormone therapy. Moreover, somatic aberrations such as androgen receptor, DNA-repair genes and tumorsuppressor genes (PTEN, TP53 and RBI) are also expected to act as biomarkers for therapeutic selection in CRPC. We herein report the significance of genetic polymorphism and somatic gene aberration in pharmacotherapy for prostate cancer, and we also present the current status and future perspectives with regard to the development of novel therapeutics based on genome information.

Original languageEnglish
Pages (from-to)155-160
Number of pages6
JournalNishinihon Journal of Urology
Volume81
Issue number2
Publication statusPublished - Apr 1 2019

Fingerprint

Precision Medicine
Castration
Prostatic Neoplasms
Drug Therapy
docetaxel
Therapeutics
Genome
Genes
Radium
p53 Genes
Androgen Receptors
Genetic Polymorphisms
DNA Repair
Patient Selection
Androgens
Biomarkers
Hormones
Research

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

@article{5868fccd2720429fa4c897107900b95b,
title = "Establishment of precision medicine in pharmacotherapy for castration-resistant prostate cancer",
abstract = "Recently, several novel agents including abiraterone, enzalutamide, docetaxel, cabazitaxel and radium-223 have become available for the treatment of castration-resistant prostate cancer (CRPC) and as a result, prognosis has improved. However, the criteria for selection of a suitable therapy have not been established. Much research on the genome has been carried out to enable precision medicine to be applied in cases of CRPC. Among them, germline polymorphisms in genes involved in androgen metabolism, such as HSD3B1, have been supposed to be the critical determinants of therapeutic outcomes in hormone therapy. Moreover, somatic aberrations such as androgen receptor, DNA-repair genes and tumorsuppressor genes (PTEN, TP53 and RBI) are also expected to act as biomarkers for therapeutic selection in CRPC. We herein report the significance of genetic polymorphism and somatic gene aberration in pharmacotherapy for prostate cancer, and we also present the current status and future perspectives with regard to the development of novel therapeutics based on genome information.",
author = "masaki shiota and Masatoshi Eto",
year = "2019",
month = "4",
day = "1",
language = "English",
volume = "81",
pages = "155--160",
journal = "Nishinihon Journal of Urology",
issn = "0029-0726",
publisher = "Kyushu University, Faculty of Science",
number = "2",

}

TY - JOUR

T1 - Establishment of precision medicine in pharmacotherapy for castration-resistant prostate cancer

AU - shiota, masaki

AU - Eto, Masatoshi

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Recently, several novel agents including abiraterone, enzalutamide, docetaxel, cabazitaxel and radium-223 have become available for the treatment of castration-resistant prostate cancer (CRPC) and as a result, prognosis has improved. However, the criteria for selection of a suitable therapy have not been established. Much research on the genome has been carried out to enable precision medicine to be applied in cases of CRPC. Among them, germline polymorphisms in genes involved in androgen metabolism, such as HSD3B1, have been supposed to be the critical determinants of therapeutic outcomes in hormone therapy. Moreover, somatic aberrations such as androgen receptor, DNA-repair genes and tumorsuppressor genes (PTEN, TP53 and RBI) are also expected to act as biomarkers for therapeutic selection in CRPC. We herein report the significance of genetic polymorphism and somatic gene aberration in pharmacotherapy for prostate cancer, and we also present the current status and future perspectives with regard to the development of novel therapeutics based on genome information.

AB - Recently, several novel agents including abiraterone, enzalutamide, docetaxel, cabazitaxel and radium-223 have become available for the treatment of castration-resistant prostate cancer (CRPC) and as a result, prognosis has improved. However, the criteria for selection of a suitable therapy have not been established. Much research on the genome has been carried out to enable precision medicine to be applied in cases of CRPC. Among them, germline polymorphisms in genes involved in androgen metabolism, such as HSD3B1, have been supposed to be the critical determinants of therapeutic outcomes in hormone therapy. Moreover, somatic aberrations such as androgen receptor, DNA-repair genes and tumorsuppressor genes (PTEN, TP53 and RBI) are also expected to act as biomarkers for therapeutic selection in CRPC. We herein report the significance of genetic polymorphism and somatic gene aberration in pharmacotherapy for prostate cancer, and we also present the current status and future perspectives with regard to the development of novel therapeutics based on genome information.

UR - http://www.scopus.com/inward/record.url?scp=85065672793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065672793&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85065672793

VL - 81

SP - 155

EP - 160

JO - Nishinihon Journal of Urology

JF - Nishinihon Journal of Urology

SN - 0029-0726

IS - 2

ER -